Luminex (LMNX) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Luminex (NASDAQ:LMNX) announced its quarterly earnings results on Monday. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.11, Bloomberg Earnings reports. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The company had revenue of $78.20 million for the quarter, compared to analysts’ expectations of $77.33 million. During the same quarter in the previous year, the company earned $0.11 earnings per share. Luminex’s quarterly revenue was up 8.2% on a year-over-year basis.

Luminex (NASDAQ:LMNX) opened at $19.31 on Tuesday. Luminex has a 52-week low of $17.68 and a 52-week high of $22.42. The stock has a market cap of $839.68, a PE ratio of 29.26, a P/E/G ratio of 1.82 and a beta of 0.13.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend is Thursday, March 22nd. Luminex’s dividend payout ratio is currently 36.36%.

Several equities analysts recently issued reports on the stock. BidaskClub upgraded shares of Luminex from a “strong sell” rating to a “sell” rating in a research report on Saturday, February 3rd. Jefferies Group reiterated a “hold” rating and set a $21.00 price target on shares of Luminex in a research report on Friday, October 20th. TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 1st. Finally, BTIG Research assumed coverage on shares of Luminex in a research report on Friday, January 5th. They set a “buy” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $22.33.

In related news, Director G Walter Loewenbaum II sold 50,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $21.79, for a total transaction of $1,089,500.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 131,698 shares of company stock worth $2,761,201 in the last three months. 6.90% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Luminex (LMNX) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Earnings History for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with's FREE daily email newsletter.

Leave a Reply